RLF sells its subsidiary to Sonnet BioTherapeutics Holdings, Inc

6 April 2020

RELIEF THERAPEUTICS Holding SA (SIX:RLF; "Relief Holding") announces today the closing of the binding Share Exchange Agreement for the acquisition by Sonnet BioTherapeutics, Inc. ("Sonnet"), now a subsidiary of Sonnet BioTherapeutics Holdings, Inc. (formerly known as Chanticleer Holdings, Inc.) (Nasdaq:SONN) of Relief Therapeutics SA ("Relief SA"), a subsidiary of Relief Holding, signed August 12, 2019. As a consequence, Sonnet acquires all outstanding shares of Relief SA that becomes a wholly owned Geneva-based subsidiary of Sonnet. In counterpart, Sonnet paid to Relief Holding shares of its common stock that converted into 757,933 shares of listed Sonnet Holdings common stock.

VISCHER advises the selling shareholder. The team was led by Damien Conus (Partner, head of Geneva M&A/Start-up desks).

Press release RELIEF THERAPEUTICS